In recent years, with the acceleration of the approval and review of new drugs, the approval speed of domestic innovative products has accelerated
significantly.
Haitong Securities Research Report said that in 2021, the number of domestic innovative drugs approved reached 28, an increase of more
than twice that of 2020.
Entering 2022, there are also domestic new drugs on the market, such as Kangfang Bio's cardonizumab, Hengrui Pharmaceutical's reveruamide, Luoxin Pharmaceutical's tigola tablets, etc.
According to the People's Financial Innovation Drug Database, only in the first half of this year, 9 domestic innovative drugs (including vaccines) were approved for the first time, and 10 innovative drugs were approved for new indications
.
Soochow Securities mentioned in a recent research report that 65 domestic innovative drugs were approved, assuming that the sales of each innovative drug is 1 billion yuan, and the terminal market is only 65 billion yuan, assuming that with the gradual increase in the proportion of medical insurance payment, the corresponding terminal market of the domestic innovative drug market is 700 billion yuan, and there is still nearly 10x growth space
.
The domestic innovative drug market has nearly 10x growth space, or brings demand expansion to the upstream (Source: Pharmaceutical Network)
Under the domestic innovative drug outlet, the industry is expected to bring expansion
to the upstream pharmaceutical equipment industry.
Under the domestic innovative drug outlet, the industry is expected to bring expansion
to the upstream pharmaceutical equipment industry.
It is understood that the performance of some companies on the pharmaceutical equipment track is ushering in rapid growth
.
In the first half of this year, the profit growth rate of the pharmaceutical equipment industry remained at about 10%, of which the industry head represented by Chutian Technology and Dongfulong performed more brightly, and the growth rate of revenue and net profit was higher
.
Chutian Technology 2022 interim report shows that the company's main revenue of 2.
871 billion yuan, up 20.
04% year-on-year; Net profit attributable to the mother was 299 million yuan, up 26.
74%
year-on-year.
Dongfulong's semi-annual report shows that in the first half of the year, the company achieved operating income of about 2.
427 billion yuan, an increase of 34.
11% year-on-year; The net profit attributable to the shareholders of the listed company was 402 million yuan, an increase of 18.
33%
year-on-year.
The eye-catching performance of the head enterprise has also attracted the attention
of the institution.
For example, Chutian Technology has frequently been investigated by institutions since the second half of the year, of which on September 16, Chutian was investigated by 2 institutions, and the institutions mainly focused on the development of microsphere business, the operation of SUT business development ROMACO this year, and the company's CGT planning
.
Guosen Securities said in a financial report review for Chutian that the company's advantageous sector has grown steadily, the biological engineering has been rapidly released, and the bioengineering sector is expected to continue to increase in volume in the future and become the core profit contribution point; At present, ROMACO has sufficient orders in hand, and with the improvement of the impact of the epidemic, it is expected to improve in the second half of the year; In addition, the company's production capacity construction continues, and the orders in hand are sufficient
.
The bank believes that the gradual increase in orders for biological drugs and non-crown products fully compensates for the sharp decline in orders related to new crown vaccines, laying the foundation for the company's subsequent stable and high-quality growth
.
For another example, Dongfulong accepted a survey of more than 150 institutions on August 30, and the company's business situation and future planning are also the focus of
institutional attention.
On the issue of how to view the development trend of the biopharmaceutical equipment industry, Dongfulong said that in general, the development of pharmaceutical equipment is closely related
to the innovative development direction of downstream drugs.
At present, innovative drugs represented by monoclonal antibodies, double antibodies, adcs and innovative vaccines have gradually matured; High-end complex injection preparations in the field of small molecule injections are also an important development direction
.
It believes that with the development of downstream innovative drugs, the company's related products will also be further applied
.
So, what kind of pharmaceutical equipment companies can stand out in the future? In the view of industry insiders, as domestic innovative drugs have been approved for listing, the commercialization process has accelerated, the demand for intelligent and green high-end pharmaceutical equipment will grow, and the head enterprises with strong research and development capabilities and rich product lines will embrace new opportunities
.
The above-mentioned person pointed out that now that the policy side has supported the high-end development of domestic pharmaceutical equipment, pharmaceutical machinery enterprises should pay attention to innovation, increase investment in research and development, and create innovative equipment with independent research and development capabilities; On the other hand, talent is an indispensable driving force for the innovation and development of enterprises, and we should attach importance to the strength of the talent team, improve the treatment and status of talents, better play the advantages of talents, and make them have a greater willingness to invest in
new innovations.
